Showing 3241-3250 of 4110 results for "".
- Núria Perez-Cullell Appointed CEO of Pierre Fabre Dermo-Cosmeticshttps://practicaldermatology.com/news/nria-perez-cullell-appointed-ceo-of-pierre-fabre-dermo-cosmetics/2457679/Ms. Núria PerezCullell is the new CEO of The Pierre Fabre Group’s Pierre Fabre Dermo-Cosmetics (PFDC) subsidiary. This appointment will take effect on August 20, 2018. Núria Perez-Cullell will take over from Mr. Eric Ducournau, whose appointment to the position of Pier
- Game On: Head-to-head Trials to Enhance Competition in PsO Markethttps://practicaldermatology.com/news/head-to-head-trials-to-enhance-competition-in-pso-market/2457684/An increase in head-to-head trials will enhance the competition within the psoriasis market, according to
- Breaking News: Galderma Skinpact Awards Deadline Extended!https://practicaldermatology.com/news/breaking-news-galderma-skinpact-awards-deadline-extended/2457683/The new deadline for the Galderma Skinpact Awards is July 31, 2018. The awards are a social responsibility program by Galderma International in partnership with the Canadian Dermatology Association, and the Women's Dermatolo
- AD Takes Big Toll on QOLhttps://practicaldermatology.com/news/ad-takes-a-big-toll-on-qol/2457691/Itch, dryness and other eczema symptoms negatively affect quality of life, according to a new study published in the Annals of Allergy, Asthma and Immunology. Of 602 adults with eczema, symptoms that were the bigg
- New From Candela: Vbeam Primahttps://practicaldermatology.com/news/new-from-candela-vbeam-prima/2457694/Recently FDA-cleared, the Vbeam Prima from Candela offers two wavelengths to effectively treat a broad range of skin condi
- Sensus Healthcare Forms Strategic Agreement with SkinCure Oncologyhttps://practicaldermatology.com/news/sensus-healthcare-forms-strategic-agreement-with-skincure-oncology/2457697/Sensus Healthcare, Inc., which specializes in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), formed a strategic agreement focused on marketing the SRT-100 Vision with SkinCure Oncology, a leading turnkey provider
- Dermtech's Noninvasive Melanoma Screen Improves Care, Lowers Costhttps://practicaldermatology.com/news/dermtechs-noninvasive-melanoma-screen-improves-care-lowers-cost/2457700/New research shows that DermTech’s Pigmented Lesion Assay (PLA) reduces cost while improving the care of patients with primary pigmented skin lesions suggestive of melanoma. The
- Rare Pediatric Skin Conditions Often Get Expensive, Inconsistent Carehttps://practicaldermatology.com/news/rare-pediatric-skin-conditions-often-get-expensive-inconsistent-care/2457704/Children with Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have high rates of complications — resulting in long and costly hospital stays — and that treatment strategies varied among health care providers, according to the first large-scale analysis, which is
- Jury Still Out on Environmental Effects of Chemical Sunscreenshttps://practicaldermatology.com/news/jury-still-out-on-environmental-effects-of-chemical-sunscreens/2457705/In the wake of Hawaiian legislation banning the sale and distribution of sunscreens containing oxybenzone and octinoxate because they may contribute to coral bleaching, new research reviews the available data on chemical ultraviolet filters found in U.S. sunscreens. The
- XELJANZ Receives EU Marketing Authorization for Adults with Active PsAhttps://practicaldermatology.com/news/xeljanz-receives-eu-marketing-authorization-for-adults-with-active-psa/2457706/The European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) in combination with methotrexate (MTX) for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease-mod